SCHEMBL7559528

SCHEMBL7559528

CC(C)=Cc1ccc(C(=O)O)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.70
POLB P06746 2/20 0.70
TDP1 Q9NUW8 2/20 0.70
GLA P06280 1/20 0.70
L3MBTL1 Q9Y468 1/20 0.70
TP53 P04637 2/20 0.55
TSHR P16473 1/20 0.55
KMT2A Q03164 1/20 0.52
RARG P13631 10/20 0.50
RARB P10826 9/20 0.50
RARA P10276 7/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
RXRA P19793 4/20 0.49
NPC1 O15118 2/20 0.49
LMNA P02545 2/20 0.49
RECQL P46063 2/20 0.49
RAB9A P51151 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
KDM4E B2RXH2 1/20 0.49
CYP26A1 O43174 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8623373 0.94 ALDH1A1 (0.63) ALDH1A1POLBTDP1GLAL3MBTL1
SCHEMBL901113 0.84 ALDH1A1 (0.68) ALDH1A1POLBTDP1GLAL3MBTL1
SCHEMBL901112 0.84 ALDH1A1 (0.68) ALDH1A1POLBTDP1GLAL3MBTL1
SCHEMBL2554589 0.83 ALDH1A1 (1.00) ALDH1A1POLBTDP1GLAL3MBTL1
SCHEMBL3218915 0.83 AKR1C3 (0.67) ALDH1A1POLBTDP1GLAL3MBTL1
Terephthalic Acid SCHEMBL27501159 0.80 TSHR (0.67) ALDH1A1POLBTDP1GLAL3MBTL1
SCHEMBL2464948 0.80 ESR1 (0.46) ALDH1A1POLBTDP1GLAL3MBTL1
SCHEMBL319810 0.79 ALDH1A1 (0.61) ALDH1A1POLBTDP1GLAL3MBTL1
SCHEMBL319809 0.79 ALDH1A1 (0.61) ALDH1A1POLBTDP1GLAL3MBTL1
SCHEMBL10529261 0.79 NR4A1 (0.56) ALDH1A1POLBTDP1GLAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0194693-B1 POLYPRENYL COMPOUNDS, PROCESSES FOR PREPARING THEM, AND PHARMACEUTICAL COMPOSITION CONTAINING THEM Eisai Co., Ltd. (JP) 1989-07-26 EP claimed
US-4788330-A Polyprenyl compounds EISAI CO., LTD. (JP) 1988-11-29 US claimed
EP-0194693-A1 Polyprenyl compounds, processes for preparing them, and pharmaceutical composition containing them Eisai Co., Ltd. (JP) 1986-09-17 EP claimed
US-20240043281-A1 TITANIUM ZIRCONIUM OXIDE NANOPARTICLES, PHOTORESIST AND PATTERNING METHOD THEREFOR, AND METHOD FOR GENERATING PRINTED CIRCUIT BOARD BEIJING VFORTUNE NEW ENERGY POWER TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2024-02-08 US disclosed
WO-2022121888-A1 TITANIUM ZIRCONIUM OXIDE NANOPARTICLES, PHOTORESIST AND PATTERNING METHOD THEREFOR, AND METHOD FOR GENERATING PRINTED CIRCUIT BOARD 清华大学 2022-06-16 WO disclosed
WO-2022033366-A1 PHOTORESIST COMPOSITION, METHOD FOR USING SAME TO FORM LITHOGRAPHIC PATTERN, AND USES OF SAME 无锡华睿芯材科技有限公司 2022-02-17 WO disclosed
WO-2022033367-A1 PHOTORESIST, METHOD FOR PATTERNING PHOTORESIST, AND METHOD FOR ETCHING INTEGRATED CIRCUIT BOARD 无锡华睿芯材科技有限公司 2022-02-17 WO disclosed
WO-2021259092-A1 PHOTORESIST COMPOSITION AND METHOD FOR FORMING THIN FILM PATTERN AND ARRAY SUBSTRATE BY USING SAME 无锡华睿芯材科技有限公司 2021-12-30 WO disclosed
CN-111704723-B Composition, zirconium-based metal crosslinked polymeric network, separator and preparation method thereof, and electrochemical cell 清华大学 2021-06-15 CN disclosed
CN-111704723-A Composition, zirconium-based metal crosslinked polymeric network, separator and preparation method thereof, and electrochemical cell 清华大学 2020-09-25 CN disclosed
US-20100190766-A1 ANTIBACTERIAL AGENTS ACHAOGEN, INC. (US) 2010-07-29 US disclosed
US-20090215814-A1 Method of inhibiting neurotrophin-receptor binding QUEEN'S UNIVERSITY AT KINGSTON (CA) 2009-08-27 US disclosed
US-20080113961-A1 Immunosuppressants with low toxicity; 1-({4-Methyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid for example; autoimmune diseases and transplant rejection; N-substituted azetidine, pyrrolidine or piperidine compounds DAIICHI SANKYO COMPANY, LIMITED (JP) 2008-05-15 US disclosed
EP-1227111-A1 TRIPHENYLBORON-CONTAINING POLYMERS AND USE THEREOF Yoshitomi Fine Chemicals, Ltd. (JP) 2002-07-31 EP disclosed
US-5166405-A Polymers suitable for use as positive photoresists CIBA-GEIGY CORPORATION (US) 1992-11-24 US disclosed
US-5106932-A Polymers usable as positive photoresists CIBA-GEIGY CORPORATION (US) 1992-04-21 US disclosed
US-4883916-A ANTICHOLESTEROL, ANTIARTERIOSCELEROSIS EISAI CO., LTD. (JP) 1989-11-28 US disclosed
EP-0194693-B1 POLYPRENYL COMPOUNDS, PROCESSES FOR PREPARING THEM, AND PHARMACEUTICAL COMPOSITION CONTAINING THEM Eisai Co., Ltd. (JP) 1989-07-26 EP disclosed
US-4788330-A Polyprenyl compounds EISAI CO., LTD. (JP) 1988-11-29 US disclosed
EP-0194693-A1 Polyprenyl compounds, processes for preparing them, and pharmaceutical composition containing them Eisai Co., Ltd. (JP) 1986-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215814-A1 Method of inhibiting neurotrophin-receptor binding NGF, NTRK2, BDNF ALDH1A1 2096/4885POLB 2851/4885TDP1 1843/4885
US-20100190766-A1 ANTIBACTERIAL AGENTS MRPL21, SI, ABCB11 ALDH1A1 687/4885POLB 671/4885TDP1 3843/4885
US-20080113961-A1 Immunosuppressants with low toxicity; 1-({4-Methyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid for example; autoimmune diseases and transplant rejection; N-substituted azetidine, pyrrolidine or piperidine compounds TPMT, AZI2, IDO1 ALDH1A1 81/4885POLB 4377/4885TDP1 2109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.